Manchester

The trials here

What the 10 trials at this site are about, from their registry records.

Conditions

• Amyloidosis4 trials
• High blood pressure4 trials
• Chronic kidney disease1 trial
• Dermatomyositis and polymyositis (myositis)1 trial
• Sarcoidosis1 trial

Phase

• Phase 36 trials
• Phase 23 trials
• Phase 2/31 trial

Status

• Completed5 trials
• Recruiting3 trials
• Active, not recruiting1 trial
• Enrolling by invitation1 trial

Lead sponsor

• Alnylam Pharmaceuticals8 trials
• Priovant Therapeutics, Inc.2 trials

Running trials

• Recruiting

  Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease

  NCT07181109· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT07052903· Phase 3· Alnylam Pharmaceuticals· Source

• Recruiting

  A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

  NCT06978725· Phase 2/3· Priovant Therapeutics, Inc.· Source

  Contact: Clinical Trial Administrator

• Enrolling by invitation

  A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT06679946· Phase 3· Alnylam Pharmaceuticals· Source

• Active, not recruiting

  HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy

  NCT04153149· Phase 3· Alnylam Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Amyloidosis2 recruiting
• High blood pressure1 recruiting
• Sarcoidosis1 recruiting

Closed trials

• Completed

  Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)

  NCT06272487· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis

  NCT05437263· Phase 3· Priovant Therapeutics, Inc.· Source

• Completed

  Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)

  NCT05103332· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension

  NCT04936035· Phase 2· Alnylam Pharmaceuticals· Source

• Completed

  APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy)

  NCT03997383· Phase 3· Alnylam Pharmaceuticals· Source